<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01439074</url>
  </required_header>
  <id_info>
    <org_study_id>PUMA 418</org_study_id>
    <nct_id>NCT01439074</nct_id>
  </id_info>
  <brief_title>Mepilex Ag Versus Silver Sulfadiazine in Children and Adults With Burn Injuries.</brief_title>
  <official_title>An Open, Randomized, Comparative, Multi-centre Investigation Evaluating the Efficacy and Tolerance of Mepilex Ag Versus Silver Sulfadiazine in the Treatment of Deep Partial Thickness Burn Injuries.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Molnlycke Health Care AB</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Molnlycke Health Care AB</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose is to compare time to healing using absorbent foam silver dressing (Mepilex Ag)
      compared to a silver sulfadiazine (SSD) 1% cream in the treatment of partial thickness burn
      injuries.284 in-patients in 8-12 centres in China will be evaluated. Treatment period will be
      up to 4 weeks with either Mepilex Ag or SSD.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects enrolled in this investigation were in-patients at eleven centers in China. To be
      included, subjects had to have deep partial-thickness burn injuries. The subjects were
      consecutively allocated to a subject code providing they fulfilled all inclusion criteria and
      none of the exclusion criteria and had signed a written informed consent form. Two evaluators
      independent of each other made the judgment regarding depth of the burn before enrolling a
      subject. The subjects were randomized to either receive Mepilex Ag or SSD.

      Treatment period were up to four weeks with either SSD or Mepilex Ag. Changes of the
      investigation products were performed according to a standardized schedule, unless the wound
      healed before.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2011</start_date>
  <completion_date type="Actual">September 2013</completion_date>
  <primary_completion_date type="Actual">September 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to Healing</measure>
    <time_frame>4 weeks</time_frame>
    <description>Healing will be defined as number of days</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent of Burn Epithelised/Healed</measure>
    <time_frame>4 weeks</time_frame>
    <description>Healing will be defined as 95% or more epithelialisation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Dressing Changes</measure>
    <time_frame>4 weeks</time_frame>
    <description>Number of dressing changes including first assembly</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>% of Study Burn Healed After One Week</measure>
    <time_frame>1 week</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">162</enrollment>
  <condition>Burn Injuries</condition>
  <arm_group>
    <arm_group_label>Mepilex Ag</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Mepilex Ag consists of a Safetac(R) soft silicone wound contact layer, a grey absorbent polyurethane foam pad containing a silver compound, activated carbon, and a vapour permeable waterproof film.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Silver Sulphadiazine Ag cream</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>SSD Ag cream is white cream, 1% SSD Ag, 40g/tube This cream is indicated for prevent and treat secondary wound infection of small area, mild burn/scald.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Mepilex Ag</intervention_name>
    <description>Dressing</description>
    <arm_group_label>Mepilex Ag</arm_group_label>
    <other_name>Absorbent foam silver dressing</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Silver Sulphadiazine Ag cream</intervention_name>
    <description>A cream used on burnt areas.</description>
    <arm_group_label>Silver Sulphadiazine Ag cream</arm_group_label>
    <other_name>SSD Ag cream, 1% SSD Ag, 40g/tube</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects with a deep partial-thickness burn injury covering 2.5%-25% TBSA (3rd degree
             areas not to exceed 10% TBSA)

          -  Burn of thermal origin

          -  Both gender with an age ≥5 years and ≤65 years at ICF

          -  Understood and signed informed consent

          -  Subjects who are younger than the legal consenting age must have a legally authorized
             representative

        One study burn should be chosen which fulfil the following criteria;

          1. isolated burn area (not head and/or face)

          2. 2nd degree deep partial

          3. area is from 1 to 10% BSA

        All deep 2nd degree burn should be treated with the investigation product, Mepilex Ag/SSD
        (according to the randomization).

        Exclusion Criteria:

          -  Burns &quot;occurred&quot; equal to or older than 36 hours

          -  Burns of chemical and electrical origin

          -  Clinically infected burn (as judged by the investigator)

          -  Subjects with lung injury or subjects being on a ventilator

          -  Treatment of the burn with an active agent before study entry. SSD is allowed up to 24
             hours prior to randomization

          -  Subjects with dermatologic skin disorders or necrotizing processes

          -  Diagnosed underlying disease(s) (e.g. HIV/AIDS, cancer and severe anaemia) judged by
             the investigator to be a potential interference in the treatment

          -  Subjects with insulin dependent diabetes mellitus

          -  Subjects treated with systemic glucocorticosteroids, except Subjects taking occasional
             doses or doses less than 10mg prednisolon (day or equivalent

          -  Use of immunosuppressive agents, radiation or chemotherapy within the past 30 days

          -  Known allergy/hypersensitivity to any of the components (SSD , Ag glycerin,
             monostearate, glycerol, cetearyl alcohol, leveling agent O, albolene, light liquid
             paraffin, ethylparaben/ silicone, polyurethane foam pad containing a silver compound,
             activated carbon)of the investigation products

          -  Subjects with physical and/or mental conditions that are not expected to comply with
             the investigation

          -  Participation in other clinical investigation(s) within 1 month prior to start of the
             investigation

          -  Pregnancy (pregnancy test needed if they do not use contraceptive)

          -  Previously randomized to this investigation (PUMA 418
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zia Zhaofan</last_name>
    <role>Principal Investigator</role>
    <affiliation>Changahai Hospital of Shanghai</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The 1st People's Hospital of Foshan</name>
      <address>
        <city>Guangdong</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Guangzhou red Cross Hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510220</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First People's Hospital of ZhengZhou</name>
      <address>
        <city>Zhenzhou</city>
        <state>Henan</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The 3rd People's Hospital of Wuxi</name>
      <address>
        <city>Wuxi</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beijing Jishuitan Hospital</name>
      <address>
        <city>Taiyuan</city>
        <state>Shanxi</state>
        <zip>30009</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Xijing Hospital</name>
      <address>
        <city>XiAn</city>
        <state>Shanxi</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The 2nd affiliated Hospital of KunMing Medical college</name>
      <address>
        <city>Kunming</city>
        <state>Yunnan</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beijing Children's Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Changhai Hoospital of Shanghai</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 21, 2011</study_first_submitted>
  <study_first_submitted_qc>September 21, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2011</study_first_posted>
  <results_first_submitted>September 26, 2014</results_first_submitted>
  <results_first_submitted_qc>September 26, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 1, 2014</results_first_posted>
  <last_update_submitted>November 10, 2017</last_update_submitted>
  <last_update_submitted_qc>November 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Burn injuries</keyword>
  <keyword>Mepilex Ag</keyword>
  <keyword>SSD Ag</keyword>
  <keyword>Partial thickness</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Wounds and Injuries</mesh_term>
    <mesh_term>Burns</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sulfadiazine</mesh_term>
    <mesh_term>Silver Sulfadiazine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Mepilex Ag</title>
          <description>Mepilex Ag consists of a Safetac(R) soft silicone wound contact layer, a grey absorbent polyurethane foam pad containing a silver compound, activated carbon, and a vapour permeable waterproof film.
Mepilex Ag: Dressing</description>
        </group>
        <group group_id="P2">
          <title>SSD Ag Cream</title>
          <description>Silver Sulphadiazine Ag cream
Silver sulphadiazine: Cream</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="75"/>
                <participants group_id="P2" count="87"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="66"/>
                <participants group_id="P2" count="74"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject shedding</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>ITT population/Safety population was chosen for the Overall Baseline Participants. ITT includes all Subjects, subject to at least one post-randomisation treatment and that provide some data for the primary endpoint.</population>
      <group_list>
        <group group_id="B1">
          <title>Mepilex Ag</title>
          <description>Mepilex Ag consists of a Safetac® soft silicone wound contact layer, a grey absorbent polyurethane foam pad containing a silver compound, activated carbon, and a vapour permeable waterproof film.
Mepilex Ag: Dressing</description>
        </group>
        <group group_id="B2">
          <title>SSD Ag Cream</title>
          <description>Silver Sulphadiazine Ag white cream, 1% SSD Ag, 40g/tube
Silver sulphadiazine: Cream</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="71"/>
            <count group_id="B2" value="82"/>
            <count group_id="B3" value="153"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="68"/>
                    <measurement group_id="B2" value="76"/>
                    <measurement group_id="B3" value="144"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37.0" spread="12.3"/>
                    <measurement group_id="B2" value="35.4" spread="13.2"/>
                    <measurement group_id="B3" value="36.2" spread="12.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="41"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="55"/>
                    <measurement group_id="B2" value="57"/>
                    <measurement group_id="B3" value="112"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>China</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="71"/>
                    <measurement group_id="B2" value="82"/>
                    <measurement group_id="B3" value="153"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Time to Healing</title>
        <description>Healing will be defined as number of days</description>
        <time_frame>4 weeks</time_frame>
        <population>ITT population/Safety population. ITT includes all Subjects, subject to at least one post-randomisation treatment and that provide some data for the primary endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Mepilex Ag</title>
            <description>Mepilex Ag consists of a Safetac(R) soft silicone wound contact layer, a grey absorbent polyurethane foam pad containing a silver compound, activated carbon, and a vapour permeable waterproof film.
Mepilex Ag: Dressing</description>
          </group>
          <group group_id="O2">
            <title>SSD Ag Cream</title>
            <description>Silver Sulphadiazine Ag cream
Silver sulphadiazine: Cream</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Healing</title>
          <description>Healing will be defined as number of days</description>
          <population>ITT population/Safety population. ITT includes all Subjects, subject to at least one post-randomisation treatment and that provide some data for the primary endpoint.</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="71"/>
                <count group_id="O2" value="82"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16" spread="7.27"/>
                    <measurement group_id="O2" value="17" spread="6.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Burn Epithelised/Healed</title>
        <description>Healing will be defined as 95% or more epithelialisation</description>
        <time_frame>4 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Mepilex Ag</title>
            <description>Mepilex Ag consists of a Safetac(R) soft silicone wound contact layer, a grey absorbent polyurethane foam pad containing a silver compound, activated carbon, and a vapour permeable waterproof film.
Mepilex Ag: Dressing</description>
          </group>
          <group group_id="O2">
            <title>SSD Ag Cream</title>
            <description>Silver Sulphadiazine Ag cream
Silver sulphadiazine: Cream</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Burn Epithelised/Healed</title>
          <description>Healing will be defined as 95% or more epithelialisation</description>
          <units>percentage of study burn healed</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="71"/>
                <count group_id="O2" value="82"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.1" spread="29"/>
                    <measurement group_id="O2" value="85.2" spread="27.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Dressing Changes</title>
        <description>Number of dressing changes including first assembly</description>
        <time_frame>4 weeks</time_frame>
        <population>ITT population/Safety population. ITT includes all Subjects, subject to at least one post-randomisation treatment and that provide some data for the primary endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Mepilex Ag</title>
            <description>Mepilex Ag consists of a Safetac(R) soft silicone wound contact layer, a grey absorbent polyurethane foam pad containing a silver compound, activated carbon, and a vapour permeable waterproof film.
Mepilex Ag: Dressing</description>
          </group>
          <group group_id="O2">
            <title>SSD Ag Cream</title>
            <description>Silver Sulphadiazine Ag cream
Silver sulphadiazine: Cream</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Dressing Changes</title>
          <description>Number of dressing changes including first assembly</description>
          <population>ITT population/Safety population. ITT includes all Subjects, subject to at least one post-randomisation treatment and that provide some data for the primary endpoint.</population>
          <units>applications</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="71"/>
                <count group_id="O2" value="82"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.1" spread="1.86"/>
                    <measurement group_id="O2" value="14.0" spread="13.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>% of Study Burn Healed After One Week</title>
        <time_frame>1 week</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Mepilex Ag</title>
            <description>Mepilex Ag consists of a Safetac(R) soft silicone wound contact layer, a grey absorbent polyurethane foam pad containing a silver compound, activated carbon, and a vapour permeable waterproof film.
Mepilex Ag: Dressing</description>
          </group>
          <group group_id="O2">
            <title>SSD Ag Cream</title>
            <description>Silver Sulphadiazine Ag cream
Silver sulphadiazine: Cream</description>
          </group>
        </group_list>
        <measure>
          <title>% of Study Burn Healed After One Week</title>
          <units>percentage of study burn healed</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="71"/>
                <count group_id="O2" value="82"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.3" spread="37.4"/>
                    <measurement group_id="O2" value="27.0" spread="30.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Mepilex Ag</title>
          <description>Mepilex Ag consists of a Safetac(R) soft silicone wound contact layer, a grey absorbent polyurethane foam pad containing a silver compound, activated carbon, and a vapour permeable waterproof film.
Mepilex Ag: Dressing</description>
        </group>
        <group group_id="E2">
          <title>SSD Ag Cream</title>
          <description>Silver Sulphadiazine Ag cream
Silver sulphadiazine: Cream</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Prof Xia, Zhaofan</name_or_title>
      <organization>Changhai Hospital of Shanghai</organization>
      <phone>+86 2181873471</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

